Markets:

Overview

News

Currencies

International

Treasuries

iShares Biotechnology ETF (NQ:IBB)

201.32 -2.94 (-1.44%)

Delayed Quote Updated: 12:55 PM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

28 29 Next >

Can Healthcare Stocks Continue To Outperform? ↗

September 26, 2022

Large-cap healthcare and biotech stocks have been resilient amidst the market turmoil caused by rising rates and the global geopolitical crisis.

Via Talk Markets

The Biotech Sector Should Come Back First ↗

September 25, 2022

We are looking for profitable opportunities to deploy dry powder. Many areas of biotech show incredible promise, including regenerative medicine, gene therapy, genomics, new advances in treating cancer...

Via Talk Markets

The Major Sector ETFs Reveal All For Investors ↗

September 06, 2022

Semiconductors have been a significant drag on Wall Street.

Via Talk Markets

Healthcare Sector Still Looks Good But Lacks Momentum ↗

September 06, 2022

The summer rally is over it’s a holiday weekend with low trading volume and bad news is pervasive. A decent jobs report on Friday brought in buyers in early hours until Russia intervened with a Nord...

Via Talk Markets

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗

August 31, 2022

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Via Benzinga

Potential Signs That Could Derail The Economy ↗

August 21, 2022

The last six weeks have brought a partial market recovery. Most of the media and financial reporters have been telling us how much better everything now seems.

Via Talk Markets

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗

August 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗

August 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗

August 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗

August 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗

August 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial ↗

August 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Biotech Investors: August's Key PDUFA Catalysts You Must Know ↗

July 31, 2022

Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the...

Via Benzinga

Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update ↗

July 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate ↗

July 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Granny Retail and Granddad Russell Dish Post FOMC ↗

July 27, 2022

If the Fed is perceived as not able to do the hard rate raise and control inflation, the consumer will continue to feel the pinch of higher prices on real goods.

Via Talk Markets

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy ↗

July 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate ↗

July 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Expectations, Implications And Possible Impacts On The Market ↗

July 25, 2022

Investors believe that the Fed Funds rate is close to peaking and will begin to decline in 2023 and 2024.

Via Talk Markets

Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact ↗

July 25, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Market Predictions 2022: When Will Stocks Go Back Up? ↗

July 22, 2022

As investors look to jump back in, they’re asking, “when will stocks go back up?” It turns out that the bulls and bears are both right.

Via InvestorPlace

Daily Biotech Pulse: VistaGen's Anxiety Study Fails, Silverback To Merge With Firm Developing EpiPen Alternative, Setback For Liminal's Lead Asset ↗

July 22, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners ↗

July 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study ↗

July 20, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings ↗

July 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

7 Biotech Stocks to Buy for Q3 ↗

July 18, 2022

These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential.

Via InvestorPlace

The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine ↗

July 18, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: FDA Signs Off Cancer Therapy Trials For NexImmune, Omega Therapeutics, Endo To Develop Rare Hereditary Skin Disease Candidate ↗

July 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures ↗

July 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

28 29 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.